The effect of different dosing regimens of motesanib on the gallbladder: a randomized phase 1b study in patients with advanced solid tumors
Lee S Rosen, Lara Lipton, Timothy J Price, Neil D Belman, Ralph V Boccia, Herbert I Hurwitz, Joe J Stephenson, Lori J Wirth, Sheryl Mccoy, Yong-jiang Hei, Cheng-Pang Hsu, Niall C Tebbutt
BMC Cancer | BMC | Published : 2013
LSR, LL, NDB, and JJS have no competing interests to declare. TJP and LJW have been consultants to Amgen Inc. RVB has received honoraria from and holds stock in Amgen Inc. HIH has received research funding from GSK. NCT has received research funding from Amgen Inc. and has provided expert testimony on behalf of Amgen Inc. SM, Y-JH, and C-PH are employees of and shareholders in Amgen Inc. The authors thank Rebeca Melara (Amgen Inc.) for pharmacokinetic analysis; Benjamin Scott (Complete Healthcare Communications, Inc., Chadds Ford, PA, USA), whose work was funded by Amgen Inc., and Beate Quednau (Amgen Inc.) for assistance in manuscript writing.